A radiation oncologist discussed the theranostics treatment landscape and career opportunities in the field at the 2025 ACRO Summit.
In an interview with CancerNetwork®, Brandon Mancini, MD, MBA, FACRO, medical director at Bold Advanced Medical Future (BAMF) health and clinical associate professor of medicine at the Michigan State University College of Human Medicine, discussed the extent of his participation in the 2025 American College of Radiation Oncology (ACRO) summit, as well as key takeaways from that work.
Mancini explained that he was part of talks and presentations that discussed the use of theranostics and radio-pharmaceutical therapy geared toward newer practitioners, which he primarily utilizes in his practice. He expressed that the participation and delivery of these events elicited robust discussion and questions regarding theranostics in practice, as well as career opportunities for those in the therapeutic radiology and radiation oncology fields.
Furthermore, Mancini described his participation in the ACRO Sharing Excellence Among Leaders (SEAL) program, wherein he delivered a presentation on the establishment of theranostics programs that can be implemented in multiple clinics nationally. He further stated that his panel included a physicist and administrator, and encompassed appropriate radio-pharmaceutical delivery, program-building tenets, and assisting the prospects of theranostics as a component of radiation oncology practice.
He concluded by expressing appreciation for having had the ability to share insights from his practice, as well as to excite professionals in the field about theranostics and radio-pharmaceutical therapy.
Transcript:
At ACRO, from a participation perspective, [many] of my contributions this year focused on the new practitioners, which are physicians that are just a few years out [of school], starting to practice on their own. I primarily utilize theranostics or radio-pharmaceutical therapy in my practice. Participating and delivering a talk or presentation to those individuals on what theranostics is and where it is going, as well as discussing unique career opportunities within radiation oncology and beyond for folks that are trained in therapeutic radiology and radiation oncology brought up a lot of good discussion and questions and answers.
I was also able to participate in the ACRO sharing excellence among leaders’ [SEAL] portion of the conference, where I delivered a presentation on theranostics, in the sense of setting up a program––certain important attributes of a radio-pharmaceutical program that can be directly implemented into multiple different clinics or centers across the country. I had an outstanding panel with a physicist and administrator going into the weeds of how to do appropriate radio-pharmaceutical treatment delivery, the important aspects to consider when building a program, and how to assist both the near-term and prospects of theranostics as a part of a radiation oncology clinic and center.
Those were incredible experiences [to have the] ability to share what I do every day and to excite or energize physicians, administrators, physicists, and beyond within the field of radiation oncology, for an important aspect of our field and our participation moving forward.